Entact Bio

Entact Bio is a preclinical stage biotechnology company focused on developing innovative medications to enhance protein function. Founded by experts in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, the company's mission is to create new medicines that restore cellular health by improving protein function. Entact Bio's unique approach involves extending the lifespan of key proteins, relocating misplaced proteins to their necessary cellular locations, and altering protein activity through structural changes. Their market focus is on addressing unmet medical needs through these novel therapeutic strategies.

Notable affiliated individuals include founders and scientists with extensive backgrounds in DUB biochemistry and drug development. The company has attracted significant interest from investors in the biotech sector, although specific names are not publicly disclosed. Key achievements include advancing their proprietary platform through preclinical stages and demonstrating potential in enhancing protein function to restore health. Entact Bio's overall impact lies in its pioneering approach to drug development, which holds promise for treating a variety of diseases by targeting protein function at a fundamental level.